Heart Failure
Conditions
Brief summary
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality. Dapagliflozin has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), in May 2020 and November 2020 respectively, for HF with reduced ejection fraction (HFrEF). The overall aim of this study is to describe the characteristics of patients initiating dapagliflozin for the treatment of HFrEF and to provide early insights into real-world dapagliflozin treatment patterns as well as patient-reported outcomes (PROs) including quality of life.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years as of study index date; the study index date is the date of initiation of treatment with dapagliflozin * Patient received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction in accordance with the local dapagliflozin product label * Signed and dated informed consent prior to enrolment in the study
Exclusion criteria
* Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin * Prior treatment with dapagliflozin or other Sodium Glucose co-transporter 2 inhibitor treatment * Initiation of dapagliflozin outside of local Heart Failure label * Diagnosis of Type 1 diabetes prior to enrolment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of other heart failure treatment initiation | Baseline to 12 months | The number of participants who initiate new heart failure medication other than dapagliflozin. |
| Time to other HF medication discontinuation | Baseline 12 months | Time from initiation of heart failure medication other than dapagliflozin until the time at which participants discontinued treatment with that medication. |
| Number of other heart failure treatment dosage changes | Baseline to 12 months | The number of participants with dosage changes for heart failure medication other than dapagliflozin. |
| Baseline characteristics (demographic and clinical) | Baseline to 12 months | To describe the baseline demographic and clinical characteristics of patients newly prescribed dapagliflozin for the treatment of Heart Failure with reduced Ejection Fraction |
| Time to discontinuation of dapagliflozin | Baseline to 12 months | Time from dapagliflozin treatment initiation until the time at which participants stop taking the medication for any reason. |
| Number of reasons for dapagliflozin treatment discontinuation | Baseline to 12 months | Number of reasons for dapagliflozin treatment discontinuation as noted by a health care professional will be extracted and described as the number and proportion of participants who have discontinued dapagliflozin according to each reasons presented. |
| Number of dapagliflozin treatment changes | Baseline to 12 months | The number of participants who switch from dapagliflozin to another Heart Failure medication. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire | Measured at enrollment, 3, 6, 9 and 12 months | The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviors occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. |
| Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score | Measured at enrollment and 3, 6, 9 and 12 months | The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Summary scores will be examined at each assessment point during follow-up. For each of the assessment periods, descriptive statistics for the observed value, change from baseline and the 95% two-sided confidence interval for the mean change will be presented. The proportions of participants with overall health status classified as poor, fair, good, and excellent will be examined at each assessment point. Additionally, the proportions of participants who experience clinically meaningful changes in overall health status: improvement (≥5 point increase), deterioration (≥5 point decrease), and stable (\<5 point increase or decrease) will be examined at each assessment point. |
Countries
Greece
Outcome results
None listed